Dulaglutide (marketed as Trulicity) is a GLP-1 receptor agonist developed by Eli Lilly, approved for type 2 diabetes management and cardiovascular risk reduction. Its unique fusion protein design provides once-weekly dosing convenience with a pre-filled, ready-to-use pen that requires no reconstitution.
Dosage Information (Research Use)
Standard initiation: 0.75mg subcutaneously once weekly. May increase to 1.5mg, 3.0mg, or 4.5mg weekly based on glycemic response. Administer on the same day each week. Prescription medication — not a research peptide.
Reconstitution & Handling
Pre-filled pen — no reconstitution required.
Half-Life & Pharmacokinetics
~5 days
Reported Observations in Literature
Common: nausea (12-21%), diarrhea (8-12%), vomiting (6-12%), abdominal pain (6-9%), decreased appetite (5-8%). Most GI effects are mild to moderate and diminish with continued use. Carries class warnings for thyroid C-cell tumors (rodent studies), pancreatitis, and renal impairment.
Key Research References
- Gerstein HC et al. “Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND).” Lancet. 2019;394:121-130
- Dungan KM et al. “Once-weekly dulaglutide versus once-daily liraglutide (AWARD-6).” Lancet. 2014;384:1349-57